Tumor-treating field devices from Novocure employ electric fields to prevent cancer cell multiplication. Its primary market is presently treating glioblastoma multiforme, the most prevalent type of brain cancer, but it also targets other solid tumors, including lung cancer. Oncology has historically concentrated on three approaches to cancer treatment: surgery, radiation, and medications. This fourth modality can coexist and improve our capacity to restrain the most lethal illnesses.
Are you enjoying this content? If yes then please support me to keep going, by subscribing for the price of a coffee, and get exclusive access to our Slack workspace with real-time notifications.
The firm is preparing for essential data readouts in the following months, enabling it to dramatically increase its addressable market in the short future. Too risky to predict clinical trials outcome? Maybe, unless a company insider thinks otherwise... This is just what happened; its CEO bought half a million dollars of Novocure stock on November 26th.
With no competitors on the horizon, protected by patents, know-how, data, and a long head start, Novocure is increasing its worldwide footprint. An overemphasis on plateauing sales in the brain cancer sector has driven the stock down more than 50%, to a cheap level for today's patient investors.
I am opening a position today.
The author of this post owns shares of NVCR. The Rookie Investor recommends NVCR. The Rookie Investor has a disclosure policy. This article by The Rookie Investor is not financial advice as it does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFD assets. Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
Have feedback on this article? Concerned about the content? Get in touch with us directly.